Sunil Healthcare Limited has successfully obtained its quarterly compliance certificate under SEBI regulations for the fourth quarter of Financial Year 2025-26. The certificate confirms the company's adherence to regulatory requirements for share dematerialization processes during the quarter ending March 31, 2026.

SEBI Compliance Certification Details

The compliance certificate was issued under Regulation 74(5) of the SEBI (Depository and Participants) Regulations, 2018. This regulation mandates specific procedures for the dematerialization of physical share certificates and requires quarterly compliance reporting.

Registrar and Transfer Agent Confirmation

Alankit Assignments Limited, serving as the company's Registrar and Transfer Agent (RTA), issued the compliance certificate on April 4, 2026. The certificate was signed by Kamal Garg, General Manager at Alankit Assignments Limited. The RTA confirmed two critical compliance aspects:

• The securities comprised in the certificates have been properly listed on the Stock Exchanges
• Physical certificates have been duly verified, mutilated, cancelled, and the depository name has been substituted in records as the registered owner

Stock Exchange Submission

Company Secretary and Compliance Officer Satyendu Pattnaik submitted the compliance certificate to both major stock exchanges on April 7, 2026. The submission was made to:

• The Bombay Stock Exchange Limited (Company Code: 537253)
• The Calcutta Stock Exchange Limited

The digital submission was completed with proper authentication, ensuring regulatory compliance and transparency in corporate governance practices.

Corporate Information

Sunil Healthcare Limited operates from its registered office at Vijay Tower, New Delhi, with CIN number L24302DL1973PLC189662. The company maintains regular compliance with SEBI regulations through its appointed RTA, Alankit Assignments Limited, which holds multiple SEBI registrations for various financial services.

Sunil Healthcare Limited has announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company's Board of Directors approved both standalone and consolidated financial results during their 266th Board Meeting held on February 06, 2026, which commenced at 4:17 p.m. and concluded at 5:55 p.m.

Q3 FY26 Financial Performance

The company's standalone financial performance for Q3 FY26 showed mixed results compared to the previous quarter. Revenue from operations declined to ₹2,183.73 lakhs from ₹2,351.76 lakhs in Q2 FY26, while net profit decreased to ₹44.30 lakhs from ₹78.90 lakhs in the previous quarter.

Nine Months Performance

For the nine months ended December 31, 2025, the standalone results showed revenue from operations of ₹6,799.69 lakhs with a net profit of ₹151.82 lakhs. Total expenses for the nine-month period amounted to ₹6,658.81 lakhs, resulting in a profit before tax of ₹220.60 lakhs.

Consolidated Results

The consolidated financial results include performance from the company's foreign subsidiaries - Sunil Healthcare Mexico Sa De CV and Sunil Healthcare North America LLC. For Q3 FY26, consolidated revenue from operations stood at ₹2,233.49 lakhs with a net profit of ₹58.52 lakhs.

Earnings Per Share and Other Details

The company reported basic and diluted earnings per share of ₹0.43 for Q3 FY26 on a standalone basis, compared to ₹0.77 in the previous quarter. For the nine months ended December 31, 2025, the earnings per share stood at ₹1.48.

Regulatory Compliance

The financial results were prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" and other accounting principles generally accepted in India. The results were reviewed by Singhi & Co., Chartered Accountants, who issued unqualified review reports for both standalone and consolidated financial statements. The company has complied with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.